On October 27, 2025 Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intelligence to accelerate drug development, reported a strategic partnership to deliver novel, scalable, and actionable insights that support biopharmaceutical innovation. This collaboration will combine unique multimodal molecular data and AI/ML technology from both companies driving advancement of novel cancer biomarkers for drug development, targeted therapies selection, and response monitoring.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The partnership will be integrated with Guardant’s broader suite of Infinity AI capabilities and exemplifies both companies’ broader commitment to harnessing AI and multimodal data to empower oncologists, researchers, and biopharma developers with solutions to transform cancer patient care.
"At Guardant Health, we’ve always believed that data is key to conquering cancer," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "By combining our industry-leading molecular data with Zephyr AI’s advanced analytics platform, we’re taking another major step toward realizing the full potential of precision oncology—helping our biopharma partners accelerate drug development and ultimately deliver better outcomes for patients worldwide."
Through the combination of Guardant Health’s multimodal real-world data and precision oncology insights and Zephyr’s proprietary AI technologies, the partnership will accelerate research and development for biopharma partners. This model is unique in its capability to generate predictions of targeted cancer therapy response validated by real-world data, integrating biologic interpretability features that result in actionable scientific intelligence.
"This collaboration represents the convergence of unmatched real-world data, leading-edge diagnostics and cutting-edge machine learning to enable more precise, scalable, and impactful oncology solutions," said Allen Chao, CEO of Zephyr AI. "By working together, Guardant Health and Zephyr AI can supercharge discovery and development needed to transform cancer treatment and deliver on the promise of personalized medicines for cancer patients."
(Press release, Guardant Health, OCT 27, 2025, View Source [SID1234657049])